#1 Clinical Trials Search in Europe

Epirubicin Hydrochloride

Epirubicin Hydrochloride is a chemotherapy drug being studied in various clinical trials for its effectiveness in treating different types of cancer. These trials aim to evaluate how well Epirubicin works alone or in combination with other drugs to combat cancers such as bladder cancer, breast cancer, liver cancer, and soft tissue sarcomas. Researchers are exploring its potential benefits, optimal dosing, and side effects to improve cancer treatment outcomes.

Table of Contents

What is Epirubicin Hydrochloride?

Epirubicin Hydrochloride is a powerful chemotherapy drug used in the treatment of various types of cancer. It belongs to a class of medications called anthracyclines, which are known for their ability to fight cancer cells[1]. Epirubicin is sometimes referred to by its brand name, which may vary depending on the manufacturer and country.

How Does Epirubicin Work?

Epirubicin works by interfering with the DNA and RNA in cancer cells. Specifically, it inhibits the synthesis of DNA and RNA, which are essential for cell growth and division. By doing this, Epirubicin can stop cancer cells from multiplying and potentially kill them[2]. This mechanism of action makes Epirubicin effective against rapidly dividing cells, which is a characteristic of many types of cancer.

What Conditions Does Epirubicin Treat?

Epirubicin Hydrochloride is used to treat several types of cancer, including:

  • Breast Cancer: It is commonly used in the treatment of various stages of breast cancer, including primary (early-stage) and advanced breast cancer[1][3].
  • Gastric Cancer (Stomach Cancer): Epirubicin is part of treatment regimens for locally advanced gastric cancer[4].
  • Soft Tissue Sarcoma: This is a type of cancer that develops in soft tissues like muscles, tendons, and blood vessels[2].
  • Hepatocellular Carcinoma (Liver Cancer): Epirubicin is used in certain treatments for liver cancer[5].
  • Other Advanced Cancers: In some cases, Epirubicin may be used to treat other types of advanced cancers[6].

How is Epirubicin Administered?

Epirubicin is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency of treatment can vary depending on the specific condition being treated and the individual patient’s needs. Some common administration methods include:

  • Intravenous infusion over 15-60 minutes[1].
  • As part of a combination therapy regimen, often given on specific days within a treatment cycle[3].
  • In some cases, it may be used in a procedure called transcatheter arterial chemoembolization (TACE) for liver cancer treatment[5]. This is a specialized procedure where the drug is delivered directly to the tumor through blood vessels.

Epirubicin in Combination Therapy

Epirubicin is often used in combination with other chemotherapy drugs to enhance its effectiveness. Some common combinations include:

  • FEC regimen: Fluorouracil, Epirubicin, and Cyclophosphamide – commonly used in breast cancer treatment[1].
  • EC regimen: Epirubicin and Cyclophosphamide – another combination used in breast cancer therapy[3].
  • ECX regimen: Epirubicin, Cisplatin, and Capecitabine – used in gastric cancer treatment[4].
  • Combination with newer targeted therapies, such as Anotinib (a multi-target tyrosine kinase inhibitor) in soft tissue sarcoma treatment[2].

Potential Side Effects

Like all chemotherapy drugs, Epirubicin can cause side effects. It’s important to discuss these with your healthcare provider. Some potential side effects include:

  • Hair loss (alopecia): This is a common side effect but is usually temporary.
  • Nausea and vomiting: These can often be managed with anti-nausea medications.
  • Bone marrow suppression: This can lead to low blood cell counts, increasing the risk of infection, anemia, and bleeding.
  • Cardiac toxicity: Epirubicin can potentially affect heart function, especially at higher cumulative doses.
  • Mouth sores
  • Skin and nail changes
  • Fatigue

Your healthcare team will monitor you closely for these and other potential side effects throughout your treatment[1][3].

Ongoing Research and Clinical Trials

Researchers continue to study Epirubicin to find new ways to use it more effectively and to reduce its side effects. Some areas of ongoing research include:

  • Optimizing dosing schedules to improve efficacy and reduce toxicity[1][3].
  • Combining Epirubicin with newer targeted therapies to enhance its effectiveness[2].
  • Exploring its use in different types of cancer and at different stages of disease[6].
  • Comparing Epirubicin to other similar drugs in various cancer treatments[5].

If you’re interested in participating in a clinical trial involving Epirubicin, discuss this option with your oncologist. They can help you understand if any current trials might be suitable for your specific situation.

Aspect Details
Cancer Types Studied Bladder cancer, breast cancer, liver cancer, soft tissue sarcomas, malignant mesothelioma
Administration Method Intravenous (IV)
Common Combinations Vinorelbine, Irinotecan, Celecoxib, Gemcitabine, Docetaxel, Thalidomide
Primary Outcomes Measured Progression-free survival, overall survival, tumor response rates
Secondary Outcomes Quality of life, toxicity profile, time to progression
Trial Phases Phase I, II, and III studies
Key Research Goals Determine optimal dosing, assess efficacy, evaluate safety profile, explore combination therapies

FAQ

  • What is Epirubicin Hydrochloride? Epirubicin Hydrochloride is a chemotherapy drug that belongs to the class of medications called anthracyclines. It works by interfering with the DNA in cancer cells, which stops them from growing and dividing.
  • What types of cancer is Epirubicin being studied for? Clinical trials are investigating Epirubicin for various cancers, including bladder cancer, breast cancer, liver cancer (hepatocellular carcinoma), soft tissue sarcomas, and malignant mesothelioma.
  • How is Epirubicin administered in these trials? In most trials, Epirubicin is given intravenously (through a vein). The dosage and frequency can vary depending on the specific trial and the type of cancer being treated.
  • Are there any common side effects of Epirubicin? While side effects can vary, some common ones may include nausea, vomiting, hair loss, and a temporary decrease in blood cell counts. The clinical trials are also studying the drug's safety profile and potential side effects.
  • How do researchers measure the effectiveness of Epirubicin in these trials? Researchers use various measures to assess Epirubicin's effectiveness, such as progression-free survival, overall survival, tumor response rates, and quality of life assessments for patients.

Ongoing Clinical Trials on Epirubicin Hydrochloride

  • Early detection of heart damage using cardiac magnetic resonance imaging in cancer patients receiving doxorubicin, epirubicin, pixantrone and other anthracyclines

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Czechia Finland France Germany Greece +8

  • Study of Patritumab Deruxtecan and Pembrolizumab for Patients with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Pembrolizumab with Chemotherapy for Patients with HER2-Negative Inflammatory Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal

  • Study on Pembrolizumab with Chemotherapy for Early-Stage Triple-Negative Breast Cancer in Patients with High TILs

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal

  • Study on 68Ga-FAPI-46 for Predicting Treatment Response in Early-Stage High-Risk Triple-Negative Breast Cancer Patients Undergoing Chemo-Immunotherapy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Bladder Cancer: Testing Cisplatin and Drug Combination for Patients with Non-Muscle Invasive Bladder Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Norway Sweden

  • Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Cyprus Czechia Denmark France Germany Italy +4

Glossary

  • Chemotherapy: A type of cancer treatment that uses drugs to destroy cancer cells.
  • Clinical Trial: A research study that tests how well new medical approaches work in people.
  • Epirubicin Hydrochloride: A chemotherapy drug used to treat various types of cancer by interfering with cancer cell DNA.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Progression-free Survival: The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival: The length of time from the start of treatment that patients are still alive.
  • Tumor Response Rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Quality of Life: The standard of health, comfort, and happiness experienced by an individual.
  • Hepatocellular Carcinoma: The most common type of primary liver cancer.
  • Soft Tissue Sarcoma: A type of cancer that begins in the soft tissues of the body, such as muscle, fat, or blood vessels.

References

  1. https://clinicaltrials.gov/study/NCT02225652
  2. https://clinicaltrials.gov/study/NCT05121350
  3. https://clinicaltrials.gov/study/NCT00617370
  4. https://clinicaltrials.gov/study/NCT01633203
  5. https://clinicaltrials.gov/study/NCT05053386
  6. https://clinicaltrials.gov/study/NCT00020748